Filter Results
:
(411)
Show Results For
-
All HBS Web
(116,010)
- Faculty Publications (411)
Show Results For
-
All HBS Web
(116,010)
- Faculty Publications (411)
- June 2018
- Supplement
Amil and the Health Care System in Brazil (B)
By: Regina Herzlinger, Ana Maria Malik, Ruth Costas and Priscilla Zogbi
Brazilian Managed Care Organization Amil faces a series of challenges while trying to redefine the terms of its relationship with hospitals and clinics and to implement a new health care model based on primary care and family medicine.
View Details
- May 2018 (Revised October 2020)
- Supplement
La Ribera Health Department (B): Epilogue
By: Regina E. Herzlinger, Emer Moloney and Daniela Beyersdorfer
The La Ribera case studies depict an innovative low cost/high quality privately financed hospital model struggling to achieve alignment with the Six Factors. It is reimbursed by the public sector in a Spanish environment whose Consumers, Structure, and Public Policy...
View Details
- February 2018
- Case
Health Savings Accounts: Enabling Consumer Participation
By: Regina E. Herzlinger and James Wallace
Health savings accounts (HSAs), a creation of the 2003 Medicare Modernization Act, had become an integral part of the drive toward consumer-driven health care. Coupled with high-deductible health plans, HSAs allowed consumers to directly control a significant part of...
View Details
- August 2017
- Teaching Note
Health Stop (A) and (B)
Teaching Note for HBS Nos. 185-084 and 196-051.
View Details
- May 2017 (Revised February 2021)
- Case
Prevent Senior: A New Paradigm for Growth in the Health Care Sector?
By: Regina E. Herzlinger, Ana Maria Malik and Priscilla Zogbi
Herzlinger, Regina E., Ana Maria Malik, and Priscilla Zogbi. "Prevent Senior: A New Paradigm for Growth in the Health Care Sector?" Harvard Business School Case 317-073, May 2017. (Revised February 2021.)
- April 2017
- Teaching Note
CV Ingenuity (A) and (B)
Teaching Note for HBS Nos. 315-045 and 315-087.
View Details
- February 2017 (Revised February 2021)
- Case
Hebrew SeniorLife: Next Steps
By: Regina E. Herzlinger, Carin-Isabel Knoop and Olivia Hull
The CEO of Hebrew SeniorLife is contemplating how to scale his highly successful but asset-intensive continuing care retirement community for elders. Among the strategies he is considering is an expansion to China; virtual web-based care; providing continuing care in...
View Details
- January 2017 (Revised March 2021)
- Case
Fitbit
By: Regina E. Herzlinger, Christine Snively and Sarah Mehta
In 2019, Fitbit lost its leadership in the wearable sensor market to Apple and to cheaper alternatives.
Why did it lose its market position?
How will the proposed acquisition affect it and Google? View Details
Why did it lose its market position?
How will the proposed acquisition affect it and Google? View Details
- September 2016
- Supplement
Vitalia Franchise (B): Vitalia Brasil
By: Regina Herzlinger, Ana Maria Malik and Andrew Otazo
This case should be distributed only after "Vitalia Franchise" (HBS Case No. 311-035) is distributed and discussed.
View Details
Herzlinger, Regina, Ana Maria Malik, and Andrew Otazo. "Vitalia Franchise (B): Vitalia Brasil." Harvard Business School Supplement 317-022, September 2016.
- September 2015 (Revised February 2023)
- Case
Emdeon's Acquisition of Change Healthcare: Innovating Transparency Solutions for Health Care Consumers
By: Regina E. Herzlinger, Jeet Guram and Aanchal Raj
Case describes acquisition of Change Healthcare, which provides health care cost and quality information, by Emdeon, a health information exchange, and discusses health care transparency. Emdeon is a billion-dollar company that has grown through acquisitions; at its...
View Details
- May 2015
- Case
Acıbadem Healthcare Group
By: Regina E. Herzlinger, Esel Çekin, Natalie Kindred and Gamze Yucaoglu
Acıbadem Healthcare Group is Turkey's only premium nationwide hospital network. This case focuses on Acıbadem’s potential expansion strategy after it was acquired by International Healthcare Holdings Berhad (IHH) in 2011, the world's second-largest publicly listed...
View Details
Herzlinger, Regina E., Esel Çekin, Natalie Kindred, and Gamze Yucaoglu. "Acıbadem Healthcare Group." Harvard Business School Case 315-120, May 2015.
- May 2015
- Supplement
OdontoPrev (B)
Herzlinger, Regina E. "OdontoPrev (B)." Harvard Business School Supplement 315-125, May 2015.
- March 2015 (Revised November 2017)
- Case
Bonitas
By: Regina E. Herzlinger and Natalie Kindred
Bonitas, a South African medical scheme (i.e., health insurer), must navigate highly restrictive regulations that make it difficult for Bonitas to innovate, grow, and compete with market leader Discovery as well as providers of alternative insurance products. Bonitas...
View Details
Keywords:
Health Insurance;
Health Care;
South Africa;
Medical Scheme;
Public Policy;
Bonitas;
Bonitas Medical Fund;
National Health Insurance;
Health;
Health Care and Treatment;
Insurance;
Policy;
Health Industry;
Insurance Industry;
South Africa;
Johannesburg;
Africa
Herzlinger, Regina E., and Natalie Kindred. "Bonitas." Harvard Business School Case 315-020, March 2015. (Revised November 2017.)
- March 2015 (Revised January 2024)
- Case
CV Ingenuity (A): How to Evaluate the Commercial Viability of New Health Care Technologies
By: Regina E. Herzlinger and Andrew Otazo
Duke Rohlen (HBS MBA ’01) hoped to win over a prominent venture capital investor for Series B financing of his firm CVI that was creating a drug-eluting balloon (DES) to treat peripheral arterial disease. As a second-mover, Duke felt he was more likely to acquire...
View Details
Keywords:
CV Ingenuity;
CVI;
Drug Eluting Balloon;
DEB;
Drug Eluting Stent;
Angioplasty Balloon;
FoxHollow;
Medical Device;
Medical Device Startup;
Premarket Approval;
PMA;
Lutonix;
Stellarex;
LEVANT;
ILLUMENATE;
Clinical Trials;
Peripheral Arterial Disease;
PAD;
Healthcare Startups;
Covidien;
Health Care and Treatment;
Health Testing and Trials;
Business Startups;
Commercialization;
Health Industry;
Medical Devices and Supplies Industry;
United States;
Europe
Herzlinger, Regina E., and Andrew Otazo. "CV Ingenuity (A): How to Evaluate the Commercial Viability of New Health Care Technologies." Harvard Business School Case 315-045, March 2015. (Revised January 2024.)
- March 2015 (Revised February 2022)
- Supplement
CV Ingenuity (B): Epilogue
By: Regina E. Herzlinger and Andrew Otazo
Duke Rohlen used a lea-nfunding, iconoclastic strategy for his start up for a drug eluding balloon for peripheral artery disease. His giant competitors were first movers. Did Duke obtain the funding he sought? How did his DEB fare versus that of his competitors?
The...
View Details
Keywords:
CV Ingenuity;
CVI;
Drug Eluting Balloon;
DEB;
Drug Eluting Stent;
Angioplasty Balloon;
FoxHollow;
Medical Device;
Medical Device Startup;
Premarket Approval;
PMA;
Lutonix;
Stellarex;
LEVANT;
ILLUMENATE;
Clinical Trials;
Peripheral Arterial Disease;
PAD;
Healthcare Startups;
Covidien;
Health Care and Treatment;
Health Testing and Trials;
Business Startups;
Commercialization;
Strategy;
Health Industry;
Medical Devices and Supplies Industry;
United States;
Europe
Herzlinger, Regina E., and Andrew Otazo. "CV Ingenuity (B): Epilogue." Harvard Business School Supplement 315-087, March 2015. (Revised February 2022.)
- Article
Market-Based Solutions to Antitrust Threats—The Rejection of the Partners Settlement
By: Regina E. Herzlinger, Barak D. Richman and Kevin A. Schulman
Keywords:
Health Care;
Health Care Industry;
Health Care Policy;
Health Care Services;
Antitrust;
Health Care and Treatment;
Health Industry;
United States
Herzlinger, Regina E., Barak D. Richman, and Kevin A. Schulman. "Market-Based Solutions to Antitrust Threats—The Rejection of the Partners Settlement." New England Journal of Medicine 372, no. 14 (April 2, 2015): 1287–1289.
- February 2015
- Supplement
MedCath Corporation (C)
By: Regina E. Herzlinger, Kevin Schulman and F. Fallon Upke
MedCath is a horizontally integrated chain of heart hospitals that partners with local cardiologists. It claims that its focus leads to better and cheaper results than those of an everything-for-everybody general hospital. Community hospitals generally vehemently...
View Details
Keywords:
Medical Specialties;
Market Entry and Exit;
Service Delivery;
Conflict and Resolution;
Horizontal Integration;
Health Industry
Herzlinger, Regina E., Kevin Schulman, and F. Fallon Upke. "MedCath Corporation (C)." Harvard Business School Supplement 315-018, February 2015.
- Blog Post
Innovation in Health Care Education: A Call to Action
By: Regina E. Herzlinger, Vasant Kumar, Kevin Schulman and Karen Staman
Health care administration educators are at a crossroads: the health care sector is rife with inefficiencies, erratic quality, unequal access, and sky-high costs, complex problems which call for innovative solutions, and yet, according to our content analysis of top...
View Details
Keywords:
Health Care;
Health Care Education;
Education;
Health;
Health Care and Treatment;
Health Industry;
Education Industry
Herzlinger, Regina E., Vasant Kumar, Kevin Schulman, and Karen Staman. "Innovation in Health Care Education: A Call to Action." Health Affairs Blog (January 29, 2015). http://healthaffairs.org/blog/2015/01/29/innovation-in-health-care-education-a-call-to-action/.
- 2015
- Other Teaching and Training Material
Innovating in Healthcare
By: Regina E. Herzlinger, Margo I. Seltzer and Kevin Schulman
With over 71,000 past enrollees, Innovating in Healthcare investigates the issues of health care spending, quality, and access that continue to plague America and global nations alike. With U.S. health care costs trending toward $4 trillion in 2020, the need to...
View Details
Herzlinger, Regina E., Margo I. Seltzer, and Kevin Schulman. "Innovating in Healthcare." edX Inc., 2015. Video. (HarvardX Massive Open Online Course.)
- December 2014 (Revised August 2015)
- Case
Improving Melanoma Screening: MELA Sciences
By: Regina E. Herzlinger, Kevin Schulman and Frédéric Dijols
MELA is a start-up medical device company looking to develop a novel technology to help physicians diagnose a deadly skin cancer, melanoma. The case reviews the FDA medical device development process, the development path pursued by MELA, and the regulatory and...
View Details